Literature DB >> 8617085

Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. A 10-year analysis of ANTADIR Observatory.

E Chailleux1, B Fauroux, F Binet, B Dautzenberg, J M Polu.   

Abstract

STUDY
OBJECTIVE: To analyze predictors of survival for patients receiving home long-term oxygen therapy (LTOT) or prolonged mechanical ventilation (PMV) according to the cause of chronic respiratory insufficiency (CRI) and the patients physiologic data.
DESIGN: Analysis of a nationwide database (ANTADIR Observatory).
SETTING: The national nonprofit network for home treatment of patients with CRI Association Nationale pour le Traitement a Domicile de lInsuffisance Respiratoire Chronique (ANTADIR); founded in France in the 1980s. PATIENTS: There were 26,140 patients receiving LTOT or PMV (noninvasive or via tracheostomy) between January 1, 1984 and January 1, 1993 (chronic bronchitis, 12,043; asthma, 1,755; bronchiectasis, 1,556; emphysema, 551; tuberculosis sequelae, 4,147; kyphoscoliosis, 1,574; neuromuscular diseases, 1,097; pneumoconiosis, 919; and fibrosis, 2,498. MEASUREMENTS AND
RESULTS: Survival analysis was performed using the actuarial and the Cox's semiparametric model. The mean survival for patients with chronic bronchitis is 3 years. Survival is slightly better for patients with bronchiectasis and asthma and worse for those with emphysema. Patients with kyphoscoliosis and a neuromuscular disease have the longest survival (8 and 6.5 years, respectively). Patients with CRI due to tuberculosis sequelae experience the same survival as COPD patients (3 years). Prognosis is the worst in patients with pneumoconiosis or fibrosis: 50% of these patients die during the year following the beginning of home treatment. The association of an obstructive lung disease worsens the prognosis of patients with kyphoscoliosis or neuromuscular disease and tends to bring the survival rate of the patients with pneumoconiosis or fibrosis closer to that of COPD patients. In COPD, male sex, older age, lower body mass index (BMI),FEV1 percent predicted,PaO2,and PaCO2 are independent negative prognostic factors. For tuberculous sequelae and kyphoscoliosis, female sex, younger age, a high BMI, PaO2 and PaCO2 (and for kyphoscoliosis a higher FEV1/vital capacity [VC] ratio) are all independent favorable prognostic factors. In pulmonary fibrosis, a lower PaO2 and PaCO2 values, a lower VC percent predicted, and a higher FEV1/VC ratio are negative prognostic factors.
CONCLUSIONS: The ANTADIR Observatory allows a unique opportunity to analyze long-term survival of a large population with CRI treated at home.

Entities:  

Mesh:

Year:  1996        PMID: 8617085     DOI: 10.1378/chest.109.3.741

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

1.  Annual report october 1998 to september 1999

Authors: 
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline.

Authors:  Douglas A McKim; Jeremy Road; Monica Avendano; Steve Abdool; Fabien Cote; Nigel Duguid; Janet Fraser; Fracois Maltais; Debra L Morrison; Colleen O'Connell; Basil J Petrof; Karen Rimmer; Robert Skomro
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 3.  Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.

Authors:  Greg Knoll; Sandra Cockfield; Tom Blydt-Hansen; Dana Baran; Bryce Kiberd; David Landsberg; David Rush; Edward Cole
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

4.  [Guidelines for home oxygen and home ventilation therapy. German Society of Pneumology, German Society of Sleep Medicine, Working Group of Nocturnal Respiratory and Cardiovascular Disorders, Working Circle of Home and Long-Term Ventilation].

Authors:  D Köhler; C P Criée; F Raschke
Journal:  Med Klin (Munich)       Date:  1997-01-15

5.  A decade of domiciliary non-invasive ventilation in the west of Ireland.

Authors:  P Gouda; J Chua; D Langan; T Hannon; A Scott; A O'Regan
Journal:  Ir J Med Sci       Date:  2016-10-15       Impact factor: 1.568

Review 6.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Authors:  Qiang Ding; Tracy Luckhardt; Louise Hecker; Yong Zhou; Gang Liu; Veena B Antony; Joao deAndrade; Victor J Thannickal
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 7.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 8.  Transplant options for end stage chronic obstructive pulmonary disease in the context of multidisciplinary treatments.

Authors:  Luigi Santambrogio; Paolo Tarsia; Paolo Mendogni; Davide Tosi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

9.  Predictors of mortality in patients with emphysema and severe airflow obstruction.

Authors:  Fernando J Martinez; Gregory Foster; Jeffrey L Curtis; Gerard Criner; Gail Weinmann; Alfred Fishman; Malcolm M DeCamp; Joshua Benditt; Frank Sciurba; Barry Make; Zab Mohsenifar; Philip Diaz; Eric Hoffman; Robert Wise
Journal:  Am J Respir Crit Care Med       Date:  2006-03-16       Impact factor: 21.405

Review 10.  Treatment of respiratory failure in COPD.

Authors:  Stephan Budweiser; Rudolf A Jörres; Michael Pfeifer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.